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The eradication of tumours by targeting malignant
stem cell populations, or cancer stem cells (CSCs), is a
promising new strategy for cancer treatment. In a paper
published in a recent issue of The EMBO Journal, pharma-
cogenetic evidence has been obtained that this is indeed
feasible in a mouse model of human chronic myeloid
leukaemia. These and further similar experiments will
be essential to determine the validity and practical useful-
ness of the CSC hypothesis.
The cancer stem cell (CSC) hypothesis, the idea that tumours are
sustained by a discrete cellular compartment with self-renewal and
tumour-reinitiating capacity, has generated both excitement and
controversy. The original observation by Dick and colleagues
(Lapidot et al, 1994; Bonnet and Dick, 1997) was that human
acute myeloid leukaemias could be re-initiated in immunodeﬁcient
mice only by a rare CD34þCD38  cell population that would
regenerate both the CSC compartment and the non-CSC bulk
tumour in the recipient. This hierarchical organization of leukae-
mias formed the conceptual basis for the CSC hypothesis, and
similar results have now been obtained in a number of tumour
types, including brain, breast, prostate, skin and intestinal cancers
(Cho and Clarke, 2008; Malanchi et al, 2008).
A corollary of the hypothesis is that speciﬁc eradication of the
CSCs would be both necessary and sufﬁcient to extinguish a tumour,
as the non-CSC tumour cells would be unable to continue prolifer-
ation in the long term. Studies that identiﬁed CSC and non-CSC
tumour fractions have relied on tumour re-initiation following trans-
plantation, rather than in situ elimination of the CSCs to establish a
hierarchical structure within the tumour. The latter type of experi-
ment is, however, necessary both to formally validate the CSC
hypothesis, and to determine its therapeutic potential, as trans-
plantation experiments face additional barriers including survival,
homing and immune rejection not present in the intact tumour, and
may therefore not accurately determine CSC activity in all cases.
The study by Pe ´rez-Caro and colleagues in a recent issue of
The EMBO Journal provides an important step forward (Pe ´rez-Caro
et al, 2009): the authors generated a mouse model of chronic
myeloid leukaemia (CML), a haematopoietic disease caused by
the oncogenic BCR–ABL fusion protein. When BCR–ABL expression
was driven from the Sca-1 promoter, which is speciﬁcally expressed
in the haematopoietic stem cells (HSCs) within the haematopoietic
system, mice developed CML-like disease, characterized by elevated
neutrophil numbers and splenomegaly with progression to blast
crisis, the acute phase of CML to which all human patients progress.
The HSC compartment is known to contain the BCR–ABL
oncoprotein in human CML, and although BCR–ABL kinase inhibi-
tors, such as imatinib/STI571, can target the bulk of the CML
tumour cells, it fails to eradicate the BCR–ABL-expressing HSCs,
which constitute the CML CSCs (Graham et al, 2002; Jorgensen and
Holyoake, 2007). By transplantation of the Lin–Sca-1þ tumour
fraction from the Sca-1 BCR–ABL transgenic mice that had develo-
ped CML-like disease, the presence of CSCs within the HSC com-
partment was conﬁrmed.
The prediction from these observations would be that elimina-
tion of the Sca-1þ cell population would be sufﬁcient to eradicate
CML in the transgenic model. This was addressed by modiﬁcation
of the transgene to include expression of the herpes simplex virus
thymidine kinase (HSV-TK), an enzyme that renders cells sensitive
to the prodrug gancyclovir (GCV). Mice expressing the Sca-1–TK-
IRES–BCR–ABL transgene also developed CML-like disease.
However, if treated with GCV 70% of the mice were able to recover.
As the bulk of the CML tumour does not express Sca-1, this showed
that the elimination of the CSC containing Sca-1þ compartment
was sufﬁcient to eradicate the disease in the majority of the cases.
These results are important, as they provide support for the
concept that speciﬁc targeting of CSCs can lead to tumour regres-
sion. It should be noted that CSCs in CML are not necessarily a static
population: evidence exists that in blast crisis CSCs with a
committed myeloid progenitor phenotype similar to the granulo-
cyte–macrophage progenitor (GMP) are generated and sustained by
ectopic b-catenin stabilization, causing activation of the canonical
Wnt pathway (Jamieson et al, 2004; Minami et al, 2008). As the Sca-
1–BCR–ABL transgenic model does not express the oncogene in this
cell population it therefore has to be considered whether restriction
of the BCR–ABL expression pattern in the mouse model used
generates a less complex, and more readily targeted, disease
compared with that occurring when BCR–ABL is more generally
expressed.
In addition, the CML induction by the Sca-1–BCR–ABL transgene
was insensitive to STI571, consistent with observations from human
tumours that BCR–ABL inhibitors were unable to efﬁciently target
the leukemogenic HSC compartment, but only the bulk tumour.
Although this reinforces the argument that the hierarchical struc-
ture of the tumours in the present transgenic model, despite the
similar pathology, may not accurately reﬂect that of human CML, it
also provides a potentially useful model system in which to
determine how BCR–ABL-expressing HSCs may be sensitized to
current or new drugs.
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